NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

by Ed Johnson
September 9, 2021
A A

–Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine
–Data from the observational cross-sectional UNIVERSE study highlight the real-world effectiveness and patient satisfaction of ubrogepant in acute migraine
–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine
–These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum

NORTH CHICAGO, Ill., Sept. 8, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from September 8-12. The company will share a total of 23 abstracts, including two oral presentations and one abstract lecture.  

“We continue to conduct research that seeks to provide additional insights into the safety, efficacy and clinical utility of our approved and investigational migraine therapies,” said Michael Gold, M.D., vice president, neuroscience development, AbbVie. “The data we’re presenting are a result of AbbVie’s ongoing commitment to driving progress in the migraine community.”

Among the new data being presented are results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluating the long-term safety and tolerability of atogepant, an investigational, orally administered calcitonin gene-related peptide receptor antagonist developed for the preventive treatment of migraine over 40 weeks. Researchers will also share data from the Phase 1, single-center, open-label, multiple-dose study assessing the potential for pharmacokinetic drug-drug interactions between atogepant and topiramate; the observational cross-sectional UNIVERSE study examining real-world effectiveness and patient satisfaction of ubrogepant for acute migraine treatment; and the POLARIS study, a retrospective claims data analysis examining the real-world treatment patterns of oral migraine preventive medication by pharmacologic class in people with migraine.

Additional presentations will focus on the efficacy of atogepant for the preventive treatment of migraine based on further analyses from the ADVANCE trial, the safety and tolerability of investigational ubrogepant as a potential acute treatment for perimenstrual migraine, and real-world evidence regarding the safety and efficacy of CGRP monoclonal antibody therapy added to BOTOX® (onabotulinumtoxinA) for migraine prevention in adult patients with chronic migraine. Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluating the use of BOTOX® for chronic migraine will also be presented.

AbbVie abstracts and presentation details for IHC 2021 are outlined below.

Abstract TitlePresentation DetailsAll times CT
Atogepant
Long-Term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of MigraineePosterSeptember 11, 20213:42 a.m. CT
Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension TrialePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Prevention of MigraineePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of MigraineePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of MigraineePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine DaysePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Daily Dosing of Oral Atogepant Improved Patient-Reported Measures of Quality of Life, Activity Impairment, and Headache Impact in a 52-week TrialePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of MigraineePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Evaluation of The Long-Term Safety and Tolerability of Oral Atogepant 60 mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the ADVANCE TrialAbstract LectureSeptember 12, 20212:45-2:55 a.m. CT
Evaluation of the Pharmacokinetic Interaction and Safety of Coadministered Atogepant and TopiramateePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Ubrogepant
Preventive Oral Migraine Treatment Utilization Patterns (POLARIS STUDY): A Retrospective Claims Data AnalysisePosterSeptember 11, 20214:51 a.m. CT
COmbining UbRogepAnt and Preventives for miGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-World EvidenceePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Ubrogepant Users’ Experience – Patients on Ubrogepant, Characteristics and Outcomes (UNIVERSE STUDY)Oral PresentationSeptember 11, 20213:20 a.m. CT
A Novel Approach to Defining Success in the Acute Treatment of Migraine: Demonstrating Therapeutic Benefit at 1 Hour Post-Dose in the Pooled ACHIEVE I and ACHIEVE II TrialsePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results From the ACHIEVE I and ACHIEVE II TrialsePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual MigraineePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Ubrogepant Treatment When Pain Is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe PainePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
BOTOX® (onabotulinumtoxinA)
Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA TreatmentePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Optimal Acute Treatment Is Associated With Productivity Gains in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyePosterSeptember 11, 20213:39 a.m. CT
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT AnalysisePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic MigraineePosterSeptember 11, 20214:12 a.m. CT
Impact of Prior Monthly Headache Days on Migraine-Related Quality of Life: Results From the CaMEO StudyePoster (on-demand only)September 8, 20211 a.m.-1:15 p.m. CT
Characterizing Preventive Treatment Gaps in Migraine: Results From the CaMEO StudyOral PresentationSeptember 10, 20218:15 a.m. CT
Tags: < Corporate Events
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Oncotelic Participating at 2023 BIO International Convention

May 17, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023

Intel and SAP Embark on Strategic Collaboration to Expand Cloud Capabilities

May 18, 2023

...

Dow and New Energy Blue to develop renewable plastic materials from corn residue.

Dow and New Energy Blue announce collaboration to develop renewable plastic materials from corn residue

May 26, 2023

...

Baxter Announces CFO Transition

May 10, 2023

...

Henkel opens Adhesive Technologies Technology Center in Bridgewater

May 17, 2023

...

3M and Svante announce joint development agreement to develop and produce carbon dioxide removal products

May 17, 2023

...

Jolyon Bulley to become Americas CEO following Elie Maalouf’s appointment to Group CEO

May 18, 2023

...

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023

...

Rockwell Automation Names Matt Fordenwalt Senior Vice President, Lifecycle Services

May 26, 2023

...

Alstom and EDC enter into a strategic partnership for sustainable mobility financing

May 17, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.